Last reviewed · How we verify
RGT001-075
At a glance
| Generic name | RGT001-075 |
|---|---|
| Sponsor | Regor Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities (PHASE2)
- Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (PHASE2)
- A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGT001-075 CI brief — competitive landscape report
- RGT001-075 updates RSS · CI watch RSS
- Regor Pharmaceuticals Inc. portfolio CI